Ocean Ranch Corporate Center

:: Back to News

Biogen Idec: A Workforce Moves In

Biogen Idec (Nasdaq:BIIB), a global leader in life sciences technology creating new standards of care in oncology and immunology, is working diligently to complete construction on 1.3 million square-feet of office, manufacturing and industrial space at Ocean Ranch Corporate Centre. Dubbed NIMO, or New Idec Manufacturing Operations, the new 90-acre endeavor is set for completion in 2005 and will be the 6th largest of its kind in the world.

The largest tenant at Ocean Ranch to date, Biogen Idec chose to situate its 14-building campus at the business park amidst several attractive offers from other locations. The company attributes that choice to the site’s direct access to the I-5 Freeway as well as its close proximity to the company’s headquarters in San Diego. In addition, the company touts Ocean Ranch Corporate Centre’s central location in a pro-business community as a significant benefit for any future development.

"Ocean Ranch Corporate Centre is a state-of-the-art industrial park located in the heart of Oceanside with easy access to freeways and close proximity to our headquarters," said Johannes Roebers, senior director of facilities and manufacturing engineering, Biogen Idec."

In a coup to the region’s economic development, the company originally purchased 60 acres of land for the endeavor, and subsequently purchased an additional 30 acres. The site is expected to generate 800 well-paying manufacturing jobs in the City of Oceanside.

As a global leader in the development, manufacturing and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. Company milestones include the discovery development, and commercialization of the first monoclonal antibody product (Rituxan(r)) and the first radioimmunotherapy product (Zevalin(r)) approved in the United States to treat cancer. The company is also developing biologics to treat autoimmune diseases.

The company also manufactures Avonex, the world’s best-selling treatment for multiple sclerosis, and Amevive, a protein indicated for the treatment of moderate to severe psoriasis currently undergoing a number of clinical trials.
Visit Biogen Idec online at www.biogenidec.com.